![Ruxandra Draghia Akli](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ruxandra Draghia Akli
Plus aucun poste en cours
Fortune : 258 486 $ au 31/05/2026
Profil
Ruxandra Draghia Akli worked at Johnson & Johnson from 2020 to 2024 as Global Head-Global Public Health R&D.
From 2024 to 2026, worked at Novavax, Inc. as EVP & Head-Research & Development.
Education includes a doctorate from Medicine & Pharmacy Carol Davila University of.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVAVAX, INC. 0,01% | 23/04/2026 | 23 563 ( 0,01% ) | 258 486 $ | 31/05/2026 |
Anciens postes connus de Ruxandra Draghia Akli
| Sociétés | Poste | Fin |
|---|---|---|
| NOVAVAX, INC. | Directeur Technique/Scientifique/R&D | 30/03/2026 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/02/2024 |
Formation de Ruxandra Draghia Akli
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
15
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
Medicine & Pharmacy Carol Davila University of
 Medicine & Pharmacy Carol Davila University of Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Choisissez Zonebourse 
